J Natl Cancer Inst. 2008 Jul 16;100(14):996-1002. doi: 10.1093/jnci/djn209. Epub 2008 Jul 8.
Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. Zacharski LR1, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW.
BACKGROUND
Excess iron has been implicated in cancer risk through increased iron-catalyzed free radical-mediated oxidative stress.
METHODS
A multicenter randomized, controlled, single-blinded clinical trial (VA Cooperative Study #410) tested the hypothesis that reducing iron stores by phlebotomy would influence vascular outcomes in patients with peripheral arterial disease. Patients without a visceral malignancy in the last 5 years (n = 1277) were randomly assigned to control (n = 641) or iron reduction (n = 636). Occurrence of new visceral malignancy and cause-specific mortality data were collected prospectively. Cancer and mortality outcomes in the two arms were compared using intent-to-treat analysis with a Cox proportional hazards regression model. Statistical tests were two-sided.
RESULTS
Patients were followed up for an average of 4.5 years. Ferritin levels were similar in both groups at baseline but were lower in iron reduction patients than control patients across all 6-month visits (mean = 79.7 ng/mL, 95% confidence interval [CI] = 73.8 to 85.5 ng/mL vs 122.5 ng/mL, 95% CI = 115.5 to 129.5 ng/mL; P < .001). Risk of new visceral malignancy was lower in the iron reduction group than in the control group (38 vs 60, hazard ratio [HR] = 0.65, 95% CI = 0.43 to 0.97; P = .036), and, among patients with new cancers, those in the iron reduction group had lower cancer-specific and all-cause mortality (HR = 0.39, 95% CI = 0.21 to 0.72; P = .003; and HR = 0.49, 95% CI = 0.29 to 0.83; P = .009, respectively) than those in the control group. Mean ferritin levels across all 6-monthly visits were similar in patients in the iron reduction and control groups who developed cancer but were lower among all patients who did not develop cancer than among those who did (76.4 ng/mL, 95% CI = 71.4 to 81.4 ng/mL, vs 127.1 ng/mL, 95% CI = 71.2 to 183.0 ng/mL; P = .017).
CONCLUSIONS
Iron reduction was associated with lower cancer risk and mortality. Further studies are needed to define the role of body iron in cancer risk.
http://www.cell.com/cell-metabolism/references/S1550-4131(16)30361-8
Authors -> Title –> Source
Anderson, E.R., Taylor, M., Xue, X., Ramakrishnan, S.K., Martin, A., Xie, L., Bredell, B.X., Gardenghi, S., Rivella, S., and Shah, Y.M. Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia.
Crossref | PubMed | Scopus (15)
Proc. Natl. Acad. Sci. USA. 2013; 110: E4922–E4930
Ashmore, J.H., Rogers, C.J., Kelleher, S.L., Lesko, S.M., and Hartman, T.J. Dietary iron and colorectal cancer risk: a review of human population studies.
Crossref
Crit. Rev. Food Sci. Nutr. 2016; 56: 1012–1020
Bao, Z.Q., Jacobsen, D.M., and Young, M.A. Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (30)
Structure. 2011; 19: 675–690
Bastide, N.M., Chenni, F., Audebert, M., Santarelli, R.L., Taché, S., Naud, N., Baradat, M., Jouanin, I., Surya, R., Hobbs, D.A. et al. A central role for heme iron in colon carcinogenesis associated with red meat intake.
Crossref | Scopus (10)
Cancer Res. 2015; 75: 870–879
Blachier, F., Vaugelade, P., Robert, V., Kibangou, B., Canonne-Hergaux, F., Delpal, S., Bureau, F., Blottière, H., and Bouglé, D. Comparative capacities of the pig colon and duodenum for luminal iron absorption.
Crossref | Scopus (16)
Can. J. Physiol. Pharmacol. 2007; 85: 185–192
Brady, D.C., Crowe, M.S., Turski, M.L., Hobbs, G.A., Yao, X., Chaikuad, A., Knapp, S., Xiao, K., Campbell, S.L., Thiele, D.J., and Counter, C.M. Copper is required for oncogenic BRAF signalling and tumorigenesis.
Crossref | PubMed | Scopus (46)
Nature. 2014; 509: 492–496
Brookes, M.J., Hughes, S., Turner, F.E., Reynolds, G., Sharma, N., Ismail, T., Berx, G., McKie, A.T., Hotchin, N., Anderson, G.J. et al. Modulation of iron transport proteins in human colorectal carcinogenesis.
Crossref | PubMed | Scopus (73)
Gut. 2006; 55: 1449–1460
Brookes, M.J., Boult, J., Roberts, K., Cooper, B.T., Hotchin, N.A., Matthews, G., Iqbal, T., and Tselepis, C. A role for iron in Wnt signalling.
Crossref | PubMed | Scopus (37)
Oncogene. 2008; 27: 966–975
Cadieux, J.A., Zhang, Z., Mattice, M., Brownlie-Cutts, A., Fu, J., Ratkay, L.G., Kwan, R., Thompson, J., Sanghara, J., Zhong, J., and Goldberg, Y.P. Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1).
Crossref | Scopus (11)
Bioorg. Med. Chem. Lett. 2012; 22: 90–95
Cancer Genome Atlas, N. and Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer.
Crossref | PubMed | Scopus (1595)
Nature. 2012; 487: 330–337
Carballo, M., Conde, M., El Bekay, R., Martín-Nieto, J., Camacho, M.J., Monteseirín, J., Conde, J., Bedoya, F.J., and Sobrino, F. Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes.
Crossref | PubMed | Scopus (163)
- Biol. Chem. 1999; 274: 17580–17586
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Crossref | PubMed | Scopus (1077)
Cancer Discov. 2012; 2: 401–404
Cross, A.J., Ferrucci, L.M., Risch, A., Graubard, B.I., Ward, M.H., Park, Y., Hollenbeck, A.R., Schatzkin, A., and Sinha, R. A large prospective study of meat consumption and colorectal cancer risk: an investigation of potential mechanisms underlying this association.
Crossref | PubMed | Scopus (127)
Cancer Res. 2010; 70: 2406–2414
Dame, M.K., Jiang, Y., Appelman, H.D., Copley, K.D., McClintock, S.D., Aslam, M.N., Attili, D., Elmunzer, B.J., Brenner, D.E., Varani, J., and Turgeon, D.K. Human colonic crypts in culture: segregation of immunochemical markers in normal versus adenoma-derived.
Crossref | Scopus (4)
Lab. Invest. 2014; 94: 222–234
Dixon, S.J. and Stockwell, B.R. The role of iron and reactive oxygen species in cell death.
Crossref | PubMed | Scopus (117)
Nat. Chem. Biol. 2014; 10: 9–17
Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (211)
Cell. 2012; 149: 1060–1072
Donovan, A., Lima, C.A., Pinkus, J.L., Pinkus, G.S., Zon, L.I., Robine, S., and Andrews, N.C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (421)
Cell Metab. 2005; 1: 191–200
Feng, Y., Sentani, K., Wiese, A., Sands, E., Green, M., Bommer, G.T., Cho, K.R., and Fearon, E.R. Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)
Am. J. Pathol. 2013; 183: 493–503
Gunshin, H., Fujiwara, Y., Custodio, A.O., Direnzo, C., Robine, S., and Andrews, N.C. Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver.
Crossref | PubMed
- Clin. Invest. 2005; 115: 1258–1266
Hinoi, T., Akyol, A., Theisen, B.K., Ferguson, D.O., Greenson, J.K., Williams, B.O., Cho, K.R., and Fearon, E.R. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation.
Crossref | PubMed | Scopus (111)
Cancer Res. 2007; 67: 9721–9730
Jarnicki, A., Putoczki, T., and Ernst, M. Stat3: linking inflammation to epithelial cancer – more than a “gut” feeling?.
Crossref | PubMed | Scopus (104)
Cell Div. 2010; 5: 14
Jenkitkasemwong, S., Wang, C.Y., Coffey, R., Zhang, W., Chan, A., Biel, T., Kim, J.S., Hojyo, S., Fukada, T., and Knutson, M.D. SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (4)
Cell Metab. 2015; 22: 138–150
Johnson, R.L. and Fleet, J.C. Animal models of colorectal cancer.
Crossref | PubMed | Scopus (16)
Cancer Metastasis Rev. 2013; 32: 39–61
Le, N.T. and Richardson, D.R. The role of iron in cell cycle progression and the proliferation of neoplastic cells.
PubMed
Biochim. Biophys. Acta. 2002; 1603: 31–46
Merk, K., Mattsson, B., Mattsson, A., Holm, G., Gullbring, B., and Björkholm, M. The incidence of cancer among blood donors.
Crossref | PubMed | Scopus (46)
Int. J. Epidemiol. 1990; 19: 505–509
Nelson, R.L. Iron and colorectal cancer risk: human studies.
Crossref | PubMed
Nutr. Rev. 2001; 59: 140–148
Nurtjahja-Tjendraputra, E., Fu, D., Phang, J.M., and Richardson, D.R. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression.
Crossref | PubMed | Scopus (74)
Blood. 2007; 109: 4045–4054
O’Shea, J.J., Holland, S.M., and Staudt, L.M. JAKs and STATs in immunity, immunodeficiency, and cancer.
Crossref | PubMed | Scopus (164)
- Engl. J. Med. 2013; 368: 161–170
Osborne, N.J., Gurrin, L.C., Allen, K.J., Constantine, C.C., Delatycki, M.B., McLaren, C.E., Gertig, D.M., Anderson, G.J., Southey, M.C., Olynyk, J.K. et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer.
Crossref | PubMed | Scopus (61)
Hepatology. 2010; 51: 1311–1318
Putoczki, T.L., Thiem, S., Loving, A., Busuttil, R.A., Wilson, N.J., Ziegler, P.K., Nguyen, P.M., Preaudet, A., Farid, R., Edwards, K.M. et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (80)
Cancer Cell. 2013; 24: 257–271
Radulescu, S., Brookes, M.J., Salgueiro, P., Ridgway, R.A., McGhee, E., Anderson, K., Ford, S.J., Stones, D.H., Iqbal, T.H., Tselepis, C., and Sansom, O.J. Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (27)
Cell Rep. 2012; 2: 270–282
Salh, B., Bergman, D., Marotta, A., and Pelech, S.L. Differential cyclin-dependent kinase expression and activation in human colon cancer.
Anticancer Res. 1999; 19: 741–748
Satyanarayana, A. and Kaldis, P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms.
Crossref | PubMed | Scopus (272)
Oncogene. 2009; 28: 2925–2939
Seril, D.N., Liao, J., Yang, G.Y., and Yang, C.S. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models.
Crossref | PubMed | Scopus (256)
Carcinogenesis. 2003; 24: 353–362
Shah, Y.M., Matsubara, T., Ito, S., Yim, S.H., and Gonzalez, F.J. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (158)
Cell Metab. 2009; 9: 152–164
Shen, J., Sheng, X., Chang, Z., Wu, Q., Wang, S., Xuan, Z., Li, D., Wu, Y., Shang, Y., Kong, X. et al. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (12)
Cell Rep. 2014; 7: 180–193
Shi, H., Bencze, K.Z., Stemmler, T.L., and Philpott, C.C. A cytosolic iron chaperone that delivers iron to ferritin.
Crossref | PubMed | Scopus (176)
Science. 2008; 320: 1207–1210
Siegel, R., Ma, J., Zou, Z., and Jemal, A. Cancer statistics, 2014.
Crossref | PubMed | Scopus (4908)
CA Cancer J. Clin. 2014; 64: 9–29
Song, S., Christova, T., Perusini, S., Alizadeh, S., Bao, R.Y., Miller, B.W., Hurren, R., Jitkova, Y., Gronda, M., Isaac, M. et al. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Crossref | PubMed | Scopus (37)
Cancer Res. 2011; 71: 7628–7639
Tak, Y.S., Tanaka, Y., Endo, S., Kamimura, Y., and Araki, H. A CDK-catalysed regulatory phosphorylation for formation of the DNA replication complex Sld2-Dpb11.
Crossref | PubMed | Scopus (56)
EMBO J. 2006; 25: 1987–1996
van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients.
Abstract | Full Text | Full Text PDF | PubMed | Scopus (49)
Cell. 2015; 161: 933–945
Xue, X. and Shah, Y.M. Hypoxia-inducible factor-2α is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer.
Crossref | PubMed | Scopus (17)
Carcinogenesis. 2013; 34: 163–169
Xue, X. and Shah, Y.M. Intestinal iron homeostasis and colon tumorigenesis.
Crossref | PubMed | Scopus (9)
Nutrients. 2013; 5: 2333–2351
Xue, Y., Ren, J., Gao, X., Jin, C., Wen, L., and Yao, X. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy.
Crossref | PubMed | Scopus (282)
Mol. Cell. Proteomics. 2008; 7: 1598–1608
Xue, X., Taylor, M., Anderson, E., Hao, C., Qu, A., Greenson, J.K., Zimmermann, E.M., Gonzalez, F.J., and Shah, Y.M. Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis.
Crossref | PubMed | Scopus (35)
Cancer Res. 2012; 72: 2285–2293
Xue, X., Ramakrishnan, S.K., and Shah, Y.M. Activation of HIF-1α does not increase intestinal tumorigenesis.
Crossref | PubMed | Scopus (8)
Am. J. Physiol. Gastrointest. Liver Physiol. 2014; 307: G187–G195
Yu, H., Pardoll, D., and Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3.
Crossref | PubMed | Scopus (1251)
Nat. Rev. Cancer. 2009; 9: 798–809
Zacharski, L.R., Chow, B.K., Howes, P.S., Shamayeva, G., Baron, J.A., Dalman, R.L., Malenka, D.J., Ozaki, C.K., and Lavori, P.W. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.
Crossref | PubMed | Scopus (133)
- Natl. Cancer Inst. 2008; 100: 996–1002
Zeestraten, E.C., Maak, M., Shibayama, M., Schuster, T., Nitsche, U., Matsushima, T., Nakayama, S., Gohda, K., Friess, H., van de Velde, C.J. et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Crossref | PubMed | Scopus (18)
Br. J. Cancer. 2012; 106: 133–140
Zhong, Z., Wen, Z., and Darnell, J.E. Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6.
Crossref | PubMed
Science. 1994; 264: 95–98
